Benjamin J. Hindson - 14 Sep 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
President and Chief Scientific Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Benjamin J. Hindson
Issuer symbol
TXG
Transactions as of
14 Sep 2022
Net transactions value
$0
Form type
4
Filing time
16 Sep 2022, 17:33:16 UTC
Previous filing
25 Aug 2022
Next filing
23 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Award $0 +33,828 +18% $0.000000 220,074 14 Sep 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Award $0 +67,655 $0.000000 67,655 14 Sep 2022 Class A Common Stock 67,655 $33.67 Direct F2
transaction TXG Performance-based Restricted Stock Units Award $0 +67,655 $0.000000 67,655 14 Sep 2022 Class A Common Stock 67,655 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs vest on each quarterly anniversary measured from August 21, 2022, subject to the Reporting Person continuing as a service provider through each such date.
F2 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 14, 2022, subject to the Reporting Person continuing as a service provider through each such date.
F3 Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/3rd of the PSUs vest upon the Issuer's Class A Common Stock achieving each of three escalating stock price milestones, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

President and Chief Scientific Officer